SCHEMBL6169927

SCHEMBL6169927

NS(=O)(=O)c1ccc(-c2c(CC(O)c3ccc(Cl)cc3)noc2-c2ccccc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 11/20 0.45
CA2 P00918 9/20 0.43
CA1 P00915 8/20 0.43
CA9 Q16790 7/20 0.43
CA12 O43570 5/20 0.43
CA14 Q9ULX7 2/20 0.43
PTGS1 P23219 2/20 0.42
MT-CO2 P00403 1/20 0.42
LMNA P02545 1/20 0.42
CA3 P07451 1/20 0.42
ADRB2 P07550 1/20 0.42
ADRB1 P08588 1/20 0.42
CYP3A4 P08684 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
CHRM1 P11229 1/20 0.42
ADRA2B P18089 1/20 0.42
CA4 P22748 1/20 0.42
CA6 P23280 1/20 0.42
SLC6A2 P23975 1/20 0.42
PDE4A P27815 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6168255 0.80 PTGS2 (0.54) PTGS2CA2CA1CA9CA12
SCHEMBL6169779 0.80 PTGS2 (0.54) PTGS2CA2CA1CA9CA12
SCHEMBL8548917 0.79 MAOA (0.45) PTGS2CA2CA1CA9CA12
SCHEMBL6167881 0.79 PTGS2 (0.62) PTGS2CA2CA1CA9CA12
SCHEMBL6169911 0.77 PTGS2 (0.53) PTGS2CA2CA1CA9CA12
SCHEMBL6168613 0.77 PTGS2 (0.57) PTGS2CA2CA1CA9CA12
SCHEMBL213407 0.77 PTGS2 (0.57) PTGS2CA2CA1CA9CA12
SCHEMBL6167937 0.76 CA2 (0.55) PTGS2CA2CA1CA9CA12
SCHEMBL6170549 0.76 CA2 (0.55) PTGS2CA2CA1CA9CA12
SCHEMBL6169873 0.75 PTGS2 (0.51) PTGS2CA2CA1CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1528059-A2 Substituted isoxazoles for the treatment of inflammation G.D. Searle LLC (US) 2005-05-04 EP claimed
EP-0809636-B1 SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION SEARLE & CO (US) 2002-09-04 EP claimed
EP-1223167-A2 Substituted isoxazoles for the treatment of inflammation G.D. Searle & Co. (US) 2002-07-17 EP claimed
EP-1528059-A2 Substituted isoxazoles for the treatment of inflammation G.D. Searle LLC (US) 2005-05-04 EP disclosed
CN-1442139-A Medicinal composition for treating inflammation SEARLE & CO (US) 2003-09-17 CN disclosed
CN-1107058-C Substituted isoxazoles for the treatment of disorders SEARLE & CO (US) 2003-04-30 CN disclosed
EP-0809636-B1 SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION SEARLE & CO (US) 2002-09-04 EP disclosed
EP-1223167-A2 Substituted isoxazoles for the treatment of inflammation G.D. Searle & Co. (US) 2002-07-17 EP disclosed
CN-1181075-A Substituted isoxazoles for the treatment of disorders SEARLE & CO (US) 1998-05-06 CN disclosed
EP-0809636-A1 SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1997-12-03 EP disclosed
WO-1996025405-A1 SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-08-22 WO disclosed